Shots:

• DotBio is eligible to receive up front and milestones along with royalties as the molecule advanced through clinical development, regulatory approvals, and commercialization
• Junshi Biosciences gets the license to one of DotBio’s DotBody modules for use in oncology to develop multi-specific cancer therapies.
• DotBio’s technology platform is based on the concept of modular design & helps to produce Abs with high efficiency and quality. The technology has been developed for autonomous folding, better stability, high expression levels, high concentration, and low aggregation

Ref: Globe Newswire | Image: PR Newswire